These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 22683513)
21. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Gouzoulis-Mayfrank E; Heekeren K; Neukirch A; Stoll M; Stock C; Obradovic M; Kovar KA Pharmacopsychiatry; 2005 Nov; 38(6):301-11. PubMed ID: 16342002 [TBL] [Abstract][Full Text] [Related]
22. Effect of MK-801 and ketamine on hydroxyl radical generation in the posterior cingulate and retrosplenial cortex of free-moving mice, as determined by in vivo microdialysis. Zuo DY; Wu YL; Yao WX; Cao Y; Wu CF; Tanaka M Pharmacol Biochem Behav; 2007 Jan; 86(1):1-7. PubMed ID: 16806445 [TBL] [Abstract][Full Text] [Related]
24. Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. Koda K; Ago Y; Cong Y; Kita Y; Takuma K; Matsuda T J Neurochem; 2010 Jul; 114(1):259-70. PubMed ID: 20403082 [TBL] [Abstract][Full Text] [Related]
25. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Kapur S; Seeman P Mol Psychiatry; 2002; 7(8):837-44. PubMed ID: 12232776 [TBL] [Abstract][Full Text] [Related]
26. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain. Bishnoi M; Chopra K; Kulkarni SK Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680 [TBL] [Abstract][Full Text] [Related]
28. The role of the mGluR allosteric modulation in the NMDA-hypofunction model of schizophrenia. Doreulee N; Alania M; Mitaishvili E; Chikovani M; Chkhartishvili B Georgian Med News; 2009 Dec; (177):59-65. PubMed ID: 20090156 [TBL] [Abstract][Full Text] [Related]
29. Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme. Siuciak JA; McCarthy SA; Chapin DS; Reed TM; Vorhees CV; Repaske DR Neuropharmacology; 2007 Jul; 53(1):113-24. PubMed ID: 17559891 [TBL] [Abstract][Full Text] [Related]
30. The effect of dopamine receptor blockade in the rodent nucleus accumbens on local field potential oscillations and motor activity in response to ketamine. Matulewicz P; Kasicki S; Hunt MJ Brain Res; 2010 Dec; 1366():226-32. PubMed ID: 20888326 [TBL] [Abstract][Full Text] [Related]
31. [Possible role of serotonin 5-HT2 receptors in mechanism of afobazole anxiolytic action: neurochemical study of inter-line differences in mice]. Raevskiĭ KS; Narkevich VB; Klodt PM; Kudrin VS Eksp Klin Farmakol; 2011; 74(12):3-7. PubMed ID: 22379873 [TBL] [Abstract][Full Text] [Related]
33. Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice. Deltheil T; Guiard BP; Cerdan J; David DJ; Tanaka KF; Repérant C; Guilloux JP; Coudoré F; Hen R; Gardier AM Neuropharmacology; 2008 Nov; 55(6):1006-14. PubMed ID: 18761360 [TBL] [Abstract][Full Text] [Related]
34. A review of NMDA receptors and the phencyclidine model of schizophrenia. Thornberg SA; Saklad SR Pharmacotherapy; 1996; 16(1):82-93. PubMed ID: 8700797 [TBL] [Abstract][Full Text] [Related]
35. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Vollenweider FX; Leenders KL; Oye I; Hell D; Angst J Eur Neuropsychopharmacol; 1997 Feb; 7(1):25-38. PubMed ID: 9088882 [TBL] [Abstract][Full Text] [Related]
36. Effect of a novel neurotensin analog, NT69L, on nicotine-induced alterations in monoamine levels in rat brain. Liang Y; Boules M; Shaw AM; Williams K; Fredrickson P; Richelson E Brain Res; 2008 Sep; 1231():6-15. PubMed ID: 18687313 [TBL] [Abstract][Full Text] [Related]
37. Subchronic ketamine treatment leads to permanent changes in EEG, cognition and the astrocytic glutamate transporter EAAT2 in mice. Featherstone RE; Liang Y; Saunders JA; Tatard-Leitman VM; Ehrlichman RS; Siegel SJ Neurobiol Dis; 2012 Sep; 47(3):338-46. PubMed ID: 22627142 [TBL] [Abstract][Full Text] [Related]
38. Antipsychotic activity of standardized Bacopa extract against ketamine-induced experimental psychosis in mice: Evidence for the involvement of dopaminergic, serotonergic, and cholinergic systems. Chatterjee M; Verma R; Kumari R; Singh S; Verma AK; Dwivedi AK; Palit G Pharm Biol; 2015; 53(12):1850-60. PubMed ID: 25856700 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of acetylcholinesterase activity and behavioural alterations induced by ketamine in an animal model of schizophrenia. Zugno AI; Matos MP; Canever L; Fraga DB; De Luca RD; Ghedim FV; Deroza PF; de Oliveira MB; Pacheco FD; Valvassori SS; Volpato AM; Budni J; Quevedo J Acta Neuropsychiatr; 2014 Feb; 26(1):43-50. PubMed ID: 25142099 [TBL] [Abstract][Full Text] [Related]
40. Reversal and Preventive Pleiotropic Mechanisms Involved in the Antipsychotic-Like Effect of Taurine, an Essential β-Amino Acid in Ketamine-Induced Experimental Schizophrenia in Mice. Ben-Azu B; Uruaka CI; Ajayi AM; Jarikre TA; Nwangwa KE; Chilaka KC; Chijioke BS; Omonyeme MG; Ozege CB; Ofili EC; Warekoromor EB; Edigbue NL; Esiekpe UV; Akaenyi DE; Agu GO Neurochem Res; 2023 Mar; 48(3):816-829. PubMed ID: 36350433 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]